Irene J. Virgolini - Search Results

Year	Number of Results
2007	1
2009	3
2010	1
2011	3
2012	5
2013	9
2014	4
2015	7
2016	3
2017	5
2018	3
2019	4
2020	4
2021	7
2022	3
2023	1
2024	0

1

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the ⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.

von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, di Santo G, Virgolini IJ. von Guggenberg E, et al. Among authors: virgolini ij. J Nucl Med. 2023 Jun;64(6):859-862. doi: 10.2967/jnumed.122.264977. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657979

2

Imaging Properties and Tumor Targeting of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.

Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg SO, Orlandi F, Mariani MF, Manzl C, Kasseroler MT, Tilg H, Zelger B, Jaschke WR, Virgolini IJ. Gruber L, et al. Among authors: virgolini ij. Biomedicines. 2022 Nov 11;10(11):2899. doi: 10.3390/biomedicines10112899. Biomedicines. 2022. PMID: 36428467 Free PMC article.

3

Repeated treatment with low dose of ¹³¹I-MIBG with good response and without toxicity.

Rossetti LM, Kroiss AS, Uprimny C, Buxbaum S, Virgolini IJ. Rossetti LM, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41 Suppl 1:S2-S3. doi: 10.1016/j.remnie.2020.09.016. Epub 2020 Dec 2. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35870835 No abstract available.

4

Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning - A retrospective analysis.

Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L, Virgolini IJ. Nilica B, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 May-Jun;41(3):138-145. doi: 10.1016/j.remnie.2021.04.007. Epub 2021 Apr 15. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35577489

5

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

Bayerschmidt S, Uprimny C, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Bayerschmidt S, et al. Diagnostics (Basel). 2021 Jun 30;11(7):1191. doi: 10.3390/diagnostics11071191. Diagnostics (Basel). 2021. PMID: 34208989 Free PMC article.

6

Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E. Hörmann AA, et al. Among authors: virgolini ij. Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575. Pharmaceuticals (Basel). 2021. PMID: 34208516 Free PMC article.

7

Repeated treatment with low dose of [¹³¹I]MIBG with good response and without toxicity.

Rossetti LM, Kroiss AS, Uprimny C, Buxbaum S, Virgolini IJ. Rossetti LM, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Apr 23:S2253-654X(20)30140-2. doi: 10.1016/j.remn.2020.08.003. Online ahead of print. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021. PMID: 33903086 English, Spanish. No abstract available.

8

Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for ⁶⁸Ga-PSMA-11 PET/CT.

Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Uprimny C, et al. J Nucl Med. 2021 Nov;62(11):1550-1557. doi: 10.2967/jnumed.120.261866. Epub 2021 Mar 12. J Nucl Med. 2021. PMID: 33712533 Free PMC article.

9

Comparison of PET/CT imaging with [¹⁸F]FDOPA and cholecystokinin-2 receptor targeting [⁶⁸Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma.

Uprimny C, von Guggenberg E, Svirydenka A, Mikołajczak R, Hubalewska-Dydejczyk A, Virgolini IJ. Uprimny C, et al. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):935-936. doi: 10.1007/s00259-020-04963-z. Epub 2020 Aug 3. Eur J Nucl Med Mol Imaging. 2021. PMID: 32748048 No abstract available.

10

Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [⁶⁸Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka A, Decristoforo C, di Santo G, von Guggenberg E, Horninger W, Virgolini IJ. Uprimny C, et al. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):123-133. doi: 10.1007/s00259-020-04846-3. Epub 2020 May 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32385647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

51 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year